Viridian Therapeutics Inc (VRDN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Viridian Therapeutics Inc (VRDN) has a cash flow conversion efficiency ratio of -0.188x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-119.65 Million) by net assets ($636.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Viridian Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Viridian Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Viridian Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Viridian Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viridian Therapeutics Inc ranked by their cash flow conversion efficiency. See VRDN operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TX Group AG
SW:TXGN
|
0.039x |
|
Jiangsu Ruitai New Energy Materials Co. Ltd.
SHE:301238
|
0.027x |
|
Hainan Haide Industry Co Ltd
SHE:000567
|
-0.099x |
|
SALZGITTER UNSP.ADR 1/10
F:SZGA
|
0.053x |
|
Kiler Holding A.S.
IS:KLRHO
|
-0.030x |
|
Taihai Manoir Nuclear Equipment Co Ltd
SHE:002366
|
-0.016x |
|
Nexa Resources SA
NYSE:NEXA
|
0.074x |
|
Arteche Lantegi Elkartea SA
MC:ART
|
0.210x |
Annual Cash Flow Conversion Efficiency for Viridian Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Viridian Therapeutics Inc from 2012 to 2025. View VRDN stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $722.17 Million | $-276.39 Million | -0.383x | -10.65% |
| 2024-12-31 | $671.64 Million | $-232.32 Million | -0.346x | +16.98% |
| 2023-12-31 | $442.02 Million | $-184.17 Million | -0.417x | -75.41% |
| 2022-12-31 | $395.06 Million | $-93.84 Million | -0.238x | +18.31% |
| 2021-12-31 | $187.72 Million | $-54.58 Million | -0.291x | -17.20% |
| 2020-12-31 | $120.04 Million | $-29.78 Million | -0.248x | +89.16% |
| 2019-12-31 | $15.75 Million | $-36.06 Million | -2.289x | -337.75% |
| 2018-12-31 | $51.34 Million | $-26.84 Million | -0.523x | +28.52% |
| 2017-12-31 | $38.51 Million | $-28.17 Million | -0.731x | -103.30% |
| 2016-12-31 | $-326.00K | $-7.23 Million | 22.181x | +3447.41% |
| 2015-12-31 | $10.41 Million | $-6.90 Million | -0.663x | -79.39% |
| 2014-12-31 | $5.99 Million | $-2.21 Million | -0.369x | +35.90% |
| 2013-12-31 | $2.03 Million | $-1.17 Million | -0.576x | -298.50% |
| 2012-12-31 | $-21.44 Million | $-6.22 Million | 0.290x | -- |
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more